Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, University of Rijeka Faculty of Medicine
InventorsOfer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
Claims13
An isolated monoclonal antibody which binds to human T-cell immunoglobulin and ITIM domain (TIGIT), or an antibody fragment thereof comprising at least the antigen binding portion of the monoclonal antibody, wherein the isolated antibody or antibody fragment is selected from the group consisting of:
- (i) an isolated antibody or antibody fragment thereof comprising six complementarity determining regions (CDRs), wherein the heavy chain (HC) CDR1 comprises the sequence GYTFTSYGIS (SEQ ID NO:1) or TSYGIS (SEQ ID NO:11);
- the HC CDR2 comprises the sequence:
- EIYPRSGNTYYNEKFKG (SEQ ID NO:2);
- the HC CDR3 comprises the sequence:
- KGPYYTKNEDY (SEQ ID NO:3);
- the light chain (LC) CDR1 comprises the sequence:
- RASEHIYYSLA (SEQ ID NO:4);
- the LC CDR2 comprises the sequence:
- NANSLED (SEQ ID NO:5);
- and the LC CDR3 comprises the sequence:
- KQAYDVPRT (SEQ ID NO:
- 6);
- and
- (ii) an isolated antibody or antibody fragment thereof comprising six CDRs, wherein the HC CDR1 comprises the sequence IYCIH (SEQ ID NO:12);
- the HC CDR2 comprises the sequence:
- EISPSNGRTIYNEKFKN (SEQ ID NO:13);
- the HC CDR3 comprises the sequence:
- SDGYDGYYFDY (SEQ ID NO:14);
- LC CDR1 comprises the sequence:
- RASQEISGYLN (SEQ ID NO:15);
- the LC CDR2 comprises the sequence:
- AASTLDS (SEQ ID NO:16);
- and the LC CDR3 comprises the sequence:
- LQYASYPRT (SEQ ID NO:17).
Dependencies are inferred from the claim text.